Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.86 |
| ▸ | ITGAV | P06756 | 20/20 | 0.86 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5972719 | 0.99 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL6944353 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL8325096 | 0.92 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL6130318 | 0.90 | ITGB3 (0.84) | ITGB3ITGAVITGA2B | |
| SCHEMBL7077079 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL8468526 | 0.90 | ITGB3 (0.77) | ITGB3ITGAVITGA2B | |
| SCHEMBL7918275 | 0.90 | ITGB3 (0.92) | ITGB3ITGAVITGA2B | |
| SCHEMBL7509393 | 0.90 | ITGB3 (0.85) | ITGB3ITGAVITGA2B | |
| SCHEMBL7510058 | 0.88 | ITGB3 (0.81) | ITGB3ITGAVITGA2B | |
| SCHEMBL7501339 | 0.87 | ITGB3 (0.81) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420792-A4 | PRODUCTS AND DRUG DELIVERY VEHICLES | SMITHKLINE BEECHAM CORP (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1341497-A4 | RECEPTOR ANTAGONIST-LIPID CONJUGATES AND DELIVERY VEHICLES CONTAINING SAME | SMITHKLINE BEECHAM CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040208844-A1 | Products and drug delivery vehicles | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| EP-1420792-A2 | PRODUCTS AND DRUG DELIVERY VEHICLES | SmithKline Beecham Corporation (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040013720-A1 | Receptor antagonist-lipid conjugates and delivery vehicles containing same | SMITHKLINE BEECHAM CORPORATION | 2004-01-22 | — | — | US | disclosed |
| EP-1341497-A2 | RECEPTOR ANTAGONIST-LIPID CONJUGATES AND DELIVERY VEHICLES CONTAINING SAME | SmithKline Beecham Corporation (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003011226-A2 | PRODUCTS AND DRUG DELIVERY VEHICLES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002036073-A2 | RECEPTOR ANTAGONIST-LIPID CONJUGATES AND DELIVERY VEHICLES CONTAINING SAME | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040013720-A1 | Receptor antagonist-lipid conjugates and delivery vehicles containing same | LDLR, LPAR2, LPAR1 | ITGB3 1479/4885ITGAV 869/4885ITGA2B 914/4885 |
| US-20040208844-A1 | Products and drug delivery vehicles | ABCB1, DDT, CHMP4B | ITGB3 2041/4885ITGAV 37/4885ITGA2B 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.